When was Syndax founded?

Syndax was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Where is Syndax located?

Syndax is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts.

How many employees does Syndax have?

As of Aug 31, 2026, the latest employee count at Syndax is 330.

Is Syndax a funded company?

Syndax is a funded company, having raised a total of $198M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 03, 2007.

When was the latest funding round of Syndax?

Syndax's latest funding was a $***** Post IPO round on Jan 31, 2020, with participation from 0 investor.

What is the annual revenue of Syndax?

Annual revenue of Syndax is between $100M and $500M as on Dec 31, 2025

Where does Syndax rank among its competitors?

Syndax ranks 7th amongst 3333 active competitors, of which 1122 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Syndax?

Syndax's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Syndax - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of targeted therapies for the treatment of cancer. The company is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer.

Website: syndax.com
Social
Registered Address: Waltham, Massachusetts

Key Metrics

Founded Year

2005

Location

Waltham, United States

Stage

Public

Total Funding

$198M in 11 rounds

Latest Funding Round

Post IPO, Jan 31, 2020, $*****

Investors

Fidelity Investments & 20 more

Ranked

7^th among 3333 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

330 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3014 more

Exit Details

Public

View Syndax's full profile

Syndax is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SYNDAX PHARMACEUTICALS INC CIN: 1395937 , United States, Active	Oct 10, 2005	$100M - $500M (As on Dec 31, 2025)	184 (As on Dec 31, 2024)	-
Syndax Pharmaceuticals, Inc. CIN: 320162505 , United States, Active	Dec 26, 999	-	268 (As on Dec 31, 2024)	-

Syndax got listed on Mar 03, 2016.

Click here to take a look at Syndax's IPO in detail

Syndax has raised a total funding of $198M over 11 rounds. Its first funding round was on Apr 03, 2007. Syndax has 21 institutional investors.

Here is the list of recent funding rounds of Syndax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 31, 2020	6417597	Post IPO	1914959	3011164	1589991	8414585
Aug 28, 2015	5697283	Series C	8015312	4317881	9847849	Orbimed & 9 more
Jun 15, 2015	6848976	Series B	9484781	4762511	7220035	2950601

Access funding benchmarks and valuations. Sign up today!

View details of Syndax's funding rounds and investors

Syndax's employee count trend

Syndax has 330 employees as of Aug 26. Here is Syndax's employee count trend over the years:

Uncover Syndax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Syndax include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Syndax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Boxer Capital, ArrowMark Partners & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100